Cargando…

Real-world effectiveness of natalizumab treatment in patients with relapsing multiple sclerosis in Argentina and Chile

BACKGROUND: The real-world effectiveness of natalizumab in people with relapsing multiple sclerosis (PwRMS) in Argentina and Chile has not been reported. OBJECTIVE: To evaluate the effectiveness of natalizumab treatment in PwRMS in Argentina and Chile, in clinical practice. METHODS: We conducted a m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ysrraelit, Maria Celica, Caride, Alejandro, Sinay, Vladimiro, Kindel, Mario Rivera, Halfon, Mario Javier, Patrucco, Liliana, Piedrabuena, Raul, Aragunde, Vanina Eleonor Diaz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academia Brasileira de Neurologia - ABNEURO 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394560/ https://www.ncbi.nlm.nih.gov/pubmed/34161529 http://dx.doi.org/10.1590/0004-282X-ANP-2020-0303

Ejemplares similares

Multiple Sclerosis and Aging: The Dynamics of Demyelination and Remyelination
por: Correale, Jorge, et al.
Publicado: (2022)

Mechanisms of Neurodegeneration and Axonal Dysfunction in Progressive Multiple Sclerosis
por: Correale, Jorge, et al.
Publicado: (2019)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis: A Cohort Study
por: Hernández-Preciado, Martha Rocio, et al.
Publicado: (2022)

Relapse-independent multiple sclerosis progression under natalizumab
por: Graf, Jonas, et al.
Publicado: (2021)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis
por: Nakamura, Masataka, et al.
Publicado: (2017)

A Model-Based Economic Evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis with High Disease Activity in Chile
por: Espinoza, Manuel Antonio, et al.
Publicado: (2021)

A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis
por: Nikfar, Shekoufeh, et al.
Publicado: (2010)

Use of Natalizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis in Kuwait
por: Alroughani, R., et al.
Publicado: (2013)

Practical Clinical Guidelines for Natalizumab Treatment in Patients With Relapsing Multiple Sclerosis
por: O'Leary, Shirley, et al.
Publicado: (2023)

A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis
por: Trojano, Maria, et al.
Publicado: (2021)

Current and emerging treatments for relapsing multiple sclerosis in Argentinian patients: a review
por: Rojas, Juan I, et al.
Publicado: (2014)

Estimating the risk of COVID-19 in multiple sclerosis patients in Buenos Aires, Argentina
por: Cristiano, E, et al.
Publicado: (2020)

Trade and competitiveness in Argentina, Brazil and Chile : not as easy as A-B-C /
Publicado: (2004)

Treatment with Natalizumab in Relapsing–Remitting Multiple Sclerosis Patients Induces Changes in Inflammatory Mechanism
por: Ramos-Cejudo, Jaime, et al.
Publicado: (2011)

Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
por: Gatzonis, Stylianos, et al.
Publicado: (2009)

Impact of Natalizumab on Ambulatory Improvement in Secondary Progressive and Disabled Relapsing-Remitting Multiple Sclerosis
por: Cadavid, Diego, et al.
Publicado: (2013)

Impact of Natalizumab Treatment on Fatigue, Mood, and Aspects of Cognition in Relapsing–Remitting Multiple Sclerosis
por: Kunkel, Annett, et al.
Publicado: (2015)

Extended Interval Dosing Natalizumab and impact on neuropsychological deficits in Relapsing-Remitting Multiple Sclerosis
por: McManus, Eileen J., et al.
Publicado: (2022)

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
por: Rezaee, Mehdi, et al.
Publicado: (2022)

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
por: van Lierop, ZYGJ, et al.
Publicado: (2021)

Typifications and synonymy in Polystichum (Dryopteridaceae) from Chile and Argentina
por: Morero, Rita E., et al.
Publicado: (2016)

Brain volume loss and physical and cognitive impairment in naïve multiple sclerosis patients treated with fingolimod: prospective cohort study in Buenos Aires, Argentina
por: Rojas, Juan Ignacio, et al.
Publicado: (2022)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life
por: Planas, Raquel, et al.
Publicado: (2014)

Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
por: Grahl, S., et al.
Publicado: (2021)

Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
por: Perumal, Jai, et al.
Publicado: (2021)

Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients
por: Johnson, Barbara H., et al.
Publicado: (2015)

Comparison of Physician Therapeutic Inertia for Management of Patients With Multiple Sclerosis in Canada, Argentina, Chile, and Spain
por: Almusalam, Noora, et al.
Publicado: (2019)

The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study
por: Mazdeh, Mehrdokht, et al.
Publicado: (2018)

Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
por: Furneri, Gianluca, et al.
Publicado: (2019)

Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
por: Perumal, Jai, et al.
Publicado: (2021)

Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
por: Alharbi, Mansour A., et al.
Publicado: (2023)

America del Sur Perú - Bolivia - Paraguay - Argentina - Chile : período nacional
por: Pereira Salas, Eugenio
Publicado: (1956)

Adaptation and validation of a Spanish version of the treatment burden questionnaire in patients with multiple sclerosis
por: Ysrraelit, María Célica, et al.
Publicado: (2019)

Incidence of COVID-19 after vaccination in people with multiple sclerosis in Argentina: Data from the nationwide registry RelevarEM
por: Rojas, Juan I., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j9565mg6kmgefjl9qt8gj7otmf